Ozempic Dosing Guide: Typical Doses & Individual Factors

Last reviewed: May 18, 2026

Last updated: May 18, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ozempic dosing for weight management typically begins at 0.25 mg weekly, escalating to a maintenance range of 0.5–2.4 mg weekly over 16 weeks. Individual responses vary significantly based on metabolic state, baseline glucose control, and genetic factors influencing medication tolerance.

Standard dosing protocols don't account for the biological variation in how your body processes GLP-1 signaling. PlexusDx emphasizes precision-informed conversations with your provider—understanding your genetic predispositions and metabolic biomarkers can support more tailored dosing discussions.

How Ozempic Dosing Works: The Titration Protocol

Ozempic uses a step-wise titration schedule to minimize gastrointestinal side effects while improving metabolic outcomes. Patients begin at 0.25 mg once weekly for four weeks, then progress to 0.5 mg weekly. Most clinical response occurs in the 1–2 mg range, with some patients continuing to 2.4 mg.

Titration pace can be adjusted based on tolerability and treatment targets. If side effects emerge, providers may extend the timeframe between dose increases. The goal is finding the lowest effective dose that achieves glycemic or weight-management outcomes while maintaining quality of life.

Factors That Shape Your Personalized Dosing Plan

Dosing decisions involve multiple clinical dimensions: baseline HbA1c or BMI, kidney function, current medications, prior GLP-1 exposure, and gastrointestinal tolerance. Providers also consider comorbidities like cardiovascular disease, which may influence the risk-benefit calculation at higher doses.

Clinical Factor	Impact on Dosing
Baseline HbA1c (diabetes)	Higher baseline often supports faster titration and higher maintenance doses
Renal function (eGFR)	Severe impairment may require cautious dosing; no dose adjustment typically needed for mild-moderate
Prior GLP-1 use	Previous exposure may inform starting dose and titration speed based on tolerance history
Gastrointestinal tolerance	Nausea or vomiting may necessitate slower titration or maintenance at lower doses
Cardiovascular history	Established heart disease may justify higher doses for cardioprotective benefit
Body weight/BMI	Obese patients may require higher doses for efficacy; lean individuals often respond at lower doses

Metabolic Biomarkers and Dose-Response Evidence

Clinical trials show dose-dependent improvements in HbA1c and weight loss. At 0.5 mg weekly, mean HbA1c reductions are approximately 1.2%, while 2.4 mg dosing achieves reductions of 1.7–2%. Weight loss similarly increases from ~4–5 kg at lower doses to 8–12 kg at maximum doses in trial populations.

However, biomarker response—changes in fasting glucose, lipids, or inflammatory markers—varies individually. Genetic variations in GLP-1 receptor sensitivity and glucose metabolism may partially explain why some patients achieve efficacy at 1 mg while others require 2–2.4 mg to reach treatment goals.

Safety Considerations and Who Should Start Ozempic

Ozempic is approved for type 2 diabetes and, in the formulation Wegovy, for chronic weight management. Contraindications include personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, and ongoing pregnancy. Patients on insulin or other glucose-lowering agents require close monitoring during titration.

Common side effects—nausea, vomiting, diarrhea—are usually dose-related and dose-limiting. Severe pancreatitis, though rare, is a serious adverse event requiring immediate provider attention. Only a qualified healthcare provider can determine whether Ozempic is appropriate for your medical situation and optimal dosing range.

How PlexusDx Supports a More Personalized Approach

Genetic variants in your GLP-1 receptor pathway may provide context for how your body responds to GLP-1 signaling. PlexusDx's Precision Peptide Genetic Test examines key variants—including GLP1R rs6923761 and GIPR rs1800437—that relate to peptide pathway sensitivity. Understanding these predispositions may help provide context for why you might respond optimally at a different dose than population averages.

The genetic test also evaluates metabolic predispositions, such as FTO rs9939609 (associated with adiposity regulation) and MC4R rs17782313 (involved in appetite signaling). These variants don't determine your exact medication response, but they can support a more informed conversation with your provider about potential dose requirements and metabolic trajectory.

When you and your provider review your genetic context alongside clinical biomarkers and tolerability, you gain a more complete picture for personalized dosing discussions. This precision-medicine approach—combining genetics, biology, and clinical judgment—may help optimize your treatment plan.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.